Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

Præstegaard, Camilla; Kjær, Susanne K.; Andersson, Michael; Steding-Jensen, Marianne; Frederiksen, Kirsten; Mellemkjær, Lene

doi:10.1007/s12282-015-0660-5

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a global public health problem, breast cancer has an increasing incidence on a global scale [1]. According to the 2017 US cancer statistics, breast cancer has become the most common malignant tumour in women, with about 250,000 new cases each year, accounting for 30% of new malignant tumours in women [2]. Therefore, the identification of risk factors for breast cancer and the adoption of effective early prevention and intervention measures are of great significance for patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Purpose: At present, the relationship between hypothyroidism and the risk of breast cancer is still inconclusive. This meta-analysis was used to systematically assess the relationship between hypothyroidism and breast cancer risk, and to assess whether thyroid hormone replacement therapy can increase breast cancer risk. Methods: The relevant articles about hypothyroidism and the risk of breast cancer were obtained on the electronic database platform. Relevant data were extracted, and odd ratios (OR) with corresponding 95% confidence intervals (CI) were merged using Stata SE 12.0 software. Results: A total of 19 related studies were included in the meta-analysis, including 6 cohort studies and 13 casecontrol studies. The results show that hypothyroidism was not related to the risk of breast cancer (odd ratios = 0.90, 95% CI 0.77-1.03). In the European subgroup, we observed that patients with hypothyroidism have a lower risk of breast cancer(odd ratios = 0.93, 95% CI 0.88-0.99). Furthermore, no significant correlation was observed between thyroid hormone replacement therapy and the risk of breast cancer. (odd ratios = 0.87, 95% CI 0.65-1.09). Conclusion: Hypothyroidism may reduce the risk of breast cancer in the European population, and no significant correlation was observed between hypothyroidism and breast cancer risk in non-European populations. Due to the limited number of studies included, more large-scale, high-quality, long-term prospective cohort studies are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In men with prostate cancer a significantly elevated risk of serious adverse effects after curative treatment has been demonstrated up to 12 years after treatment [61]. Also risks of other late effects such as second primary cancers and loss of working years have been reported based on clinical registry data [62,63].…”

Section: Monitoring Changing Principles Of Carementioning

confidence: 99%

The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

Nilbert

Thomsen

Jensen³

et al. 2020

Acta Oncologica

View full text Add to dashboard Cite

Background: In Scandinavia, there is a strong tradition for research and quality monitoring based on registry data. In Denmark, Norway and Sweden, 63 clinical registries collect data on disease characteristics, treatment and outcome of various cancer diagnoses and groups based on process-related and outcome-related variables. Aim: We describe the cancer-related clinical registries, compare organizational structures and quality indicators and provide examples of how these registries have been used to monitor clinical performance, develop prediction models, assess outcome and provide quality benchmarks. Further, we define unmet needs such as inclusion of patient-reported outcome variables, harmonization of variables and barriers for data sharing. Results and conclusions: The clinical registry framework provides an empirical basis for evidencebased development of high-quality and equitable cancer care. The registries can be used to follow implementation of new treatment principles and monitor patterns of care across geographical areas and patient groups. At the same time, the lessons learnt suggest that further developments and coordination are needed to utilize the full potential of the registry initiative in cancer care.

show abstract

“…According to the 2017 US cancer statistics, breast cancer has become the most common malignant tumour in women, with about 250,000 new cases each year, accounting for 30% of new malignant tumours in women [2]. Therefore, the identification of risk factors for breast cancer and the adoption of effective early prevention and intervention measures are of great significance for breast cancer prevention and treatment.…”

Section: Introductionmentioning

confidence: 99%

Low levels of thyroid hormone may reduce the risk of breast cancer: evidence from a meta-analysis

Wang¹,

Huang²,

Lin³

2019

Preprint

View full text Add to dashboard Cite

Background: At present, the relationship between hypothyroidism and the risk of breast cancer is still inconclusive. This meta-analysis was used to systematically assess the relationship between hypothyroidism and breast cancer risk, and to assess whether thyroid hormone replacement therapy can increase breast cancer risk.Methods: The relevant articles about hypothyroidism and the risk of breast cancer were obtained on the electronic database platform. Relevant data were extracted, and odd ratios with corresponding 95% confidence intervals(95% CI) were merged using Stata SE 12.0 software. A total of 19 related studies were included in the meta-analysis, including 6 cohort studies and 13 case-control studies.Result: The results show that hypothyroidism can reduce the risk of breast cancer(odd ratios= 0.90, 95% CI 0.77-1.03), but in Asian populations, patients with hypothyroidism have an increased risk of breast cancer(odd ratios=1.17, 95% CI 0.98-1.35). In addition, patients who received thyroid hormone replacement therapy had a lower risk of developing breast cancer(odd ratios=0.87, 95% CI 0.65-1.09).Conclusion: Hypothyroidism and thyroid hormone replacement therapy reduces the risk of breast cancer, suggesting that low levels of thyroid hormone may be beneficial to breast cancer prevention. Due to the limited number of studies included more large-scale, high-quality, long-term prospective cohort studies are needed.

show abstract

Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

Abstract: Our overall results indicate that tamoxifen is not associated with skin cancer. However, the inconsistency of results from stratifications prevents a firm conclusion.

Cited by 5 publications

References 35 publications

Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis

Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis

The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

Low levels of thyroid hormone may reduce the risk of breast cancer: evidence from a meta-analysis

Contact Info

Product

Resources

About